ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that the Regulatory Board of SIX Swiss Exchange has granted the delisting of the shares of the company (Swiss Security Number 126'004'193 / ISIN CH1260041939) from SIX Swiss Exchange and has exempted the company from certain obligations associated with the maintenance of the listing.

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that, concurrent to the decision to wind-down the company's operations, Catarina Edfjäll, Ph.D.

ObsEva Announces Update on Board of Directors

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operations with the termination of all of its employees, including Fabien de Ladonchamps, CEO, and notified SIX Swiss Exchange's listing authority that there was a substantial risk that it will lack the resources to have financial statements for 2023 prepared under IFRS audited, and that it is as a result likely not going to be able to satisfy the requirements for maintaining its listing on SIX.

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it was granted a temporary moratorium (sursis provisoire) by the competent court in Geneva, Switzerland.

Geneva Court Grants Temporary Moratorium to ObsEva

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that, following a comprehensive assessment of the company's financial position, the Board of Directors has opted to seek a moratorium from the competent court in Geneva, Switzerland.

ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that XOMA will be receiving full worldwide rights on ebopiprant, an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist, following the termination of the license agreement with Organon.

Organon Returns Ebopiprant to XOMA

ObsEva Files half Year 202 3 Financial Statements

ObsEva Files half Year 2023 Financial Statements

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland –  Ju ly 13 , 202 3  – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it has recovered full worldwide rights on nolasiban, a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in women undergoing embryo transfer after in vitro fertilization (“IVF”), following the termination of its sub-licensing agreement with Yuyuan BioScience (“Yuyuan”).

ObsEva Recovers Full Worldwide Rights on Nolasiban

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 30 , 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that shareholders approved all Board proposals at its 2023 Annual General Meeting held on June 29, 2023.

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland –  June 8 , 202 3  – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today published the invitation to its 2023 Annual General Meeting of Shareholders to be held on June 29, 2023, at 10:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.

Annual General Meeting 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – May 2 , 202 3 – ObsEva SA ( SIX: OBSN ), a biopharmaceutical company developing novel therapies for women's health, today announced that Fabien de Ladonchamps has been appointed Chief Executive Officer effective May 1, 2023.

ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland –  April 28 , 202 3  – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today published its Annual Report 2022 to Shareholders.

ObsEva Annual Report 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20 , 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF ), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it intends for its common shares to be traded under a new International Securities Identification Numbers (“ISIN”) beginning on April 25, 2023.

ObsEva Announces Change of Central Securities Depositary

ObsEva Files Year End 2022 Financial Statements

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

TOP Ships

Exela Technologies

Why penny stocks might be a better choice for some investors than blue chips The post What Do Penny Stocks Offer Over Blue Chips? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What Do Penny Stocks Offer Over Blue Chips?

Faraday Future Intelligent Electric

Genius Group Ltd

These indicators can help you to make money with penny stocks The post The Most Important Penny Stocks Trading Indicators  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The Most Important Penny Stocks Trading Indicators

Use these tips for making money with penny stocks in 2023 The post Penny Stocks Trading: How News Plays a Role appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Trading: How News Plays a Role

ObsEva (NASDAQ: OBSV ) stock is taking off on Friday as investors react to insider buying at the clinical-stage biopharmaceutical company. Ernest Loumaye, a member of the Board of Directors at ObsEva, purchased 4 million shares of OBSV stock on Tuesday.

Why Is ObsEva (OBSV) Stock Up 93% Today?

ObsEva (NASDAQ: OBSV ) stock is bouncing back on Monday after the company's stock underwent a major dip during the prior day of trading. That crash saw the company's shares fall 50.8% during Friday's normal trading hours.

Why Is ObsEva (OBSV) Stock Up 61% Today?

ObsEva (NASDAQ: OBSV ) is trending on social media, and OBSV stock is tumbling 36% to 10.85 cents. The Swiss biopharmaceutical company announced that it would undertake a major reorganization to preserve its remaining funds, noting that it “is expecting to be delisted from Nasdaq, and intends to deregister from the US Securities and Exchange Commission” ObsEva reported that it would concentrate its efforts on developing its nolasiban drug candidate.

News for ObsEva Stock (OBSV)